2021年IDF世界糖尿病大会

2021年国际糖尿病联合会(IDF)大会——世界糖尿病大会将于2021年12月6日至11日以虚拟会议形式举行。IDF大会是国际糠尿病联合会的一项核心活动，每两年在世界各地举办一次，从1952年在荷兰莱顿举行的第一次大会到最近在2019年在韩国釜山举行的IDF大会，与会人数已经从几百名增长到12,000余人。IDF世界大会提供了一个全球性的平台，以讨论广泛的糖尿病问题，从最新的科学进展到有关教育、糖尿病护理、宣宣传和认识方面的前沿信息等等。参与者包括医生、科学家、护士、教育工作者和其他医疗专业人士，以及政府代表、决策者、糖尿病患者、IDF成员和媒体代表等等。

国际糖尿病联合会（IDF）是一个由全球170个国家和地区的240多个糖尿病协会成员构成的伞状组织，代表着越来越多糖尿病患者和那些高危人群者的利益。自1950年以来，IDF一直是全球糖尿病界的领导者。IDF的使命是促进糖尿病的护理、预防和全球性的治疗。IDF的国家糖尿病协会分为七个区域：非洲、欧洲、中东和北非、北美和加勒比地区、南美和中美洲、东南亚和西太平洋，目的是促进各个国家糖尿病协会的工作并加强它们之间的合作。IDF每两年在世界各地举办一次世界大会。

International Diabetes Federation (IDF) Virtual Congress 2021

DATE: December 6-11, 2021
VENUE: Virtual

大会日程>>

The IDF Virtual Congress 2021 will take place on an interactive virtual platform on 6-11 December, 10:30-17:00 CET .

The Congress will feature the latest research on diabetes complications and COVID-19. The first day will feature a special programme dedicated to the centenary of the discovery of insulin and the IDF Diabetes Atlas 10th Edition 2021.

The interactive virtual platform will feature enhanced networking tools to allow participants to connect and collaborate with diabetes professionals from all corners of the globe.

摘要提交：

Abstract Submission : 1 June - 31 July 2021

Late-breaking abstracts (LBA): 1 September - 3 November 2021

We welcome original abstracts on subjects relevant to the following topics:

• Cardiovascular disease and hypertension
• Eye
• Foot
• Kidney
• Neuropathy
• Covid-19
• Other complications

点此提交摘要>>>Submit Abstract>>>

Abstracts accepted for the IDF Virtual Congress 2021 will be published in the IDF journal, Diabetes Research and Clinical Practice.

提交指南：

Submission mode: Abstract submission is only possible through the online congress profile platform. Abstracts submitted by post, fax or email will NOT be accepted. The online abstract submission module will NOT be available after 31 July 2021.

IDF congress profile: In order to submit an abstract, a congress profile must be created, which gives access to the online abstract submission module. The submitting author must ensure accurate contact details are entered. One or more abstracts can be submitted by logging in with a congress profile.

Submitting author/presenting author: If the submitting author is not also the presenting author, the submitting author is responsible for informing the presenting author of all communications received regarding the abstract.

Presenting author registration: The presenting author must be registered by 27 September 2021. If the presenting author is not registered by 27 September 2021, their abstract will be REMOVED from the programme.

Number of submissions: There can only be ONE presenting author per abstract. The same abstract CANNOT be submitted multiple times by listing different presenting authors. An author may submit an unlimited number of abstracts.

Language: All abstracts must be submitted in English. Should English not be your first language, it is recommended to have your abstract examined by a fluent English speaker prior to submission.

Originality of abstracts: Work published in peer-reviewed journals before 6 December 2021 should NOT be submitted to the IDF Virtual Congress 2021. Abstracts already presented at face-to-face meetings should also not be submitted, unless there are new methods and/or findings. Abstracts already presented at a national virtual meeting can be resubmitted. However, previously submitted work should NOT be resubmitted, if it was presented at an international virtual meeting.

Disclosure of interests: Any financial relationships with commercial entities related to the authors or products and processes described in the abstract must be appropriately disclosed.

Regulatory approval: The submitting author confirms that local regulatory approval has been obtained as required by local laws.

Author consent: The submitting author declares all authors have read and approved the submitted work.

Copyright transfer: Authors must attest that their submitted work does not infringe any copyright legislation. Copyright for the publication of abstracts is automatically transferred to the International Diabetes Federation upon submission and acceptance of the regulations within the online submission module.

For rejected abstracts, the copyright reverts back to the authors.

Instructions

Topic: There are various categories that have been defined for the abstract programme within the three streams. Ensure that you select the MOST relevant topic which BEST describes the content of your abstract. Categories are used for reviewing and indexing purposes.

Abstract title: The title is limited to 120 characters including spaces and should be brief and relevant. Special characters should NOT be used in your title but spelt out instead (e.g. α should be written as alpha, β as beta). Only use standard abbreviations and generic drug names in the title.

Authors: Only 12 authors and/or study groups can be listed. Only one institution can be entered per author.

Abstract body: The abstract structure is laid out under the headings
Background, Aims, Method, Results and Discussion.

Font size and style will be automatically configured by the system.

Tables will be accepted in the submission field and count towards the character limit. The character deduction for tables is not fixed and will be generated by the character count shown below the submission field. Graphs, figures and photographs are NOT allowed.

The length of the abstract is limited to 500 words. Only the abstract body and any inserted tables count towards this word limit. The word count displayed beneath the submission field is final and indisputable.

Only commonly accepted abbreviations should be used (e.g. GDM, BMI, DM). Treatment groups or drug names should NOT be abbreviated. Less widely recognised abbreviations may be used if introduced on first usage (e.g. ambulatory blood pressure monitoring, ABPM).

Only approved and generic (non-proprietary) drug names should be used.

Do NOT enter the title, authors, or grant information into the abstract body but include any references at the end of the abstract.

Selection and notification process

Selection: All submitted abstracts undergo a review process by the Programme Committee. Accepted abstracts are selected for oral poster presentation or e-poster gallery display. The Programme Committee reserves the right to accept or reject any submitted abstract and re-categorise any accepted abstract. The decision of the Programme Committee is final and irrevocable.

Notification: Notice of acceptance or rejection of submitted abstracts will be sent to the submitting authors by 9 September 2021. It is the responsibility of the submitting author to inform all other authors of the status of the abstract. A submitting author may also check their congress profile to see the status of the abstract.

Author Registration: Presenting authors of accepted abstracts MUST register for the congress by 27 September 2021. If the entire registration fee is not paid by the deadline, the abstract will be automatically withdrawn and will NOT be presented or published.

注册费：

The registration fee includes:

• Access to all live sessions through the interactive virtual platform and to recordings for 30 days after the event
• Access to all abstracts and posters through the e-poster gallery
• Access to all industry-sponsored symposia
• Access to online polling and networking sessions through zoom
• CME certification based on hours of sessions viewed

Registration rates

(1) Medical doctor & group rate
(2) Healthcare professional other than medical doctor
(3) Residents and citizens of LMIE as defined by the World Bank
(4) Student at the time of congress – not applicable to post-doctorate students
(5) Only applicable to IDF School of Diabetes learners enrolled in a premium (fee-paying) course